GAZYVA, Special Drug Use Surveillance -Patients with CD20-positive follicular lymphoma-

GAZYVA, Special Drug Use Surveillance -Patients with CD20-positive follicular lymphoma- - GAZYVA, Special Drug Use Surveillance -Patients with CD20-positive follicular lymphoma-

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033864

Enrollment

1000

Registered

2018-10-20

Start date

2018-10-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CD20-positive follicular lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with CD20-positive follicular lymphoma planning to use obinutuzumab during the enrollment period.

Exclusion criteria

Exclusion criteria: not applicable

Design outcomes

Primary

Measure	Time frame
The incidence proportion of Grade >=3 infection	—

Countries

Japan

Contacts

Public ContactAyako Murayama

Chugai Pharmaceutical Co. Ltd. Safety Science Dept.

murayamaayk@chugai-pharm.co.jp03-3281-6611

Outcome results